depression nasal spray

FDA Approves ‘Spravato’ Nasal Spray

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Popular Science · 1d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Fox Business · 2d

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

FDA approves nasal spray for treatment-resistant depression

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

FOX 341d

TTUHSC Psychiatry chairman discusses newly approved antidepressant nasal spray

The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...

16hon MSN

Seniors who are children of divorce face greater stroke risk, study finds

Seniors have a 61% higher risk of stroke if their parents divorced when they were children or teenagers, researchers reported in a study published Wednesday in the journal PLOS One.

5hon MSN

What happened in health news this week? | Health Smart

Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results